BridgeBio Oncology Therapeutics, Inc.: 5%+ holders

As of November 9, 2026, 6 holders' latest Schedule 13D or 13G filings report owning 5% or more of BridgeBio Oncology Therapeutics, Inc. The largest reported stake is Helix Holdings II LLC's, at 22.6%. 9 filings are on record since July 24, 2025 (Schedule 13D/A, August 13, 2025).

Bihua Chen also filed stake reports on 1 other company ↓

Sell to companies like BridgeBio Oncology Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-07-06 · Reporting person: Bihua Chen · Sole voting: 0 · Shared voting: 17,878,594 · Sole dispositive: 0 · Shared dispositive: 17,878,594 · SCHEDULE 13D/A, 2026-07-06
• Filed 2025-11-14 · Holder: Citadel Advisors LLC · Percent: 3.2% · SCHEDULE 13G/A
• Filed 2025-11-13 · Holder: Adage Capital Management, L.P. · Percent: 1.88% · SCHEDULE 13G/A
• Event date 2025-09-04 · Holder: BC Global Opportunities IX LP · Percent: 5.5% · Shares: 4,365,747 · SCHEDULE 13G
• Filed 2025-08-18 · Holder: BridgeBio Pharma LLC · Percent: 17.5% · SCHEDULE 13D

BridgeBio Oncology Therapeutics, Inc. has 9 Schedule 13D or 13G filings on record since 2025-07-24. 6 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind BridgeBio Oncology Therapeutics, Inc. and the warning signs.

See BridgeBio Oncology Therapeutics, Inc.'s free Snapshot Watch BridgeBio Oncology Therapeutics, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on BridgeBio Oncology Therapeutics, Inc. and the records around it.

BridgeBio Oncology Therapeutics, Inc. elsewhere on the record

• Leadership changes Jun 2026
• Who owns it

Companies that share a holder

• Bihua Chen also filed stake reports on 1 other company: MoonLake Immunotherapeutics (Oct 2025)
• Deerfield Mgmt, L.P. also filed stake reports on 19 other companies: Climb Bio, Inc. (Oct 2026), Cogent Biosciences, Inc. (Aug 2026), Enhabit, Inc. (Aug 2026)
• Sculptor Capital LP also filed stake reports on 40 other companies: Helix Acquisition Corp. III (Oct 2026), Live Oak Acquisition Corp. VI (Oct 2026), Amanat Acquisition Corp (Aug 2026)

Want the whole picture on BridgeBio Oncology Therapeutics, Inc.?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on BridgeBio Oncology Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on BridgeBio Oncology Therapeutics, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   13 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies BridgeBio Oncology Therapeutics, Inc. by CUSIP 107924102 and gives its principal executive office as 256 E Grand Avenue, Suite 104, South San Fancisco, CA 94080 (SCHEDULE 13D/A, 2026-07-06).

Purpose of Transaction (Item 4)

Helix Holdings II LLC

Item 4 is hereby amended and supplemented as follows: As previously disclosed, on February 28, 2025, the Issuer (which was formerly known as Helix Acquisition Corp. II, "Helix") entered into a Business Combination Agreement (as amended on June 20, 2025, the "Business Combination Agreement") with TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics, "Legacy BBOT"), and Helix II Merger Sub, Inc. ("Merger Sub"), pursuant to which, subject to the satisfaction or waiver of certain conditions set forth therein, the Domestication of Helix as a Delaware corporation would occur, followed by the Merger of Merger Sub with and into Legacy BBOT. Prior to the Business Combination, Ms. Chen was the Chairwoman and Chief Executive Officer of the Issuer, a shareholder of the Issuer, and a shareholder of Legacy BBOT. On August 11, 2025, the Domestication occurred. Immediately prior to the Domestication, Sponsor forfeited 307,874 Sponsor Forfeited Shares and subsequently converted an aggregate of 4,172,126 Helix Class B ordinary shares held by it, in each case pursuant to the terms of the Support Agreement. Upon the completion of the Domestication, each Helix Class A ordinary share held by the Reporting Persons automatically converted into one share of Common Stock of the Issuer, on a one-for-one basis. On August 11, 2025, the PIPE Investments closed and the Reporting Persons purchased an aggregate of 6,998,031 shares of Common Stock at a price per share of $10.7173, representing the …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-08-13; the filing has the rest

BridgeBio Pharma LLC

The Reporting Persons acquired the Shares for investment purposes in the ordinary course of business. Immediately following the Effective Time of the Business Combination, Neil Kumar, Ph.D., Chief Executive Officer and a member of the board of directors of BBIO, and Frank P. McCormick, Ph.D., F.R.S., D.Sc., Chairman of Oncology and a member of the board of directors of BBIO, were appointed to serve as directors of the Issuer. As a result of their positions, Drs. Kumar and McCormick may, from time to time, engage in discussions with the Issuer's board of directors, management, or other stockholders regarding matters relating to the Issuer's business, operations, governance, strategy, or capital structure. These discussions may include, but are not limited to: (i) the acquisition or disposition of securities of the Issuer; (ii) potential changes to the Issuer's board or management; (iii) strategic transactions, including mergers, acquisitions, or dispositions; or (iv) other matters described in paragraphs (a) through (j) of Item 4 of Schedule 13D. The Reporting Persons may also participate in discussions regarding the Issuer's strategic direction, including potential financing activities, collaborations, or licensing transactions. In connection with the foregoing, and as may be appropriate from time to time, the Reporting Persons may consider the feasibility and advisability of various alternative courses of action with respect to their investment in the Issuer, including, …The first part of Item 4 of the SCHEDULE 13D filed 2025-08-18; the filing has the rest

Bihua Chen

Item 4 is hereby amended and supplemented as follows: On July 1, 2026, Sponsor distributed 4,528,186 shares of Common Stock, pro rata, to its members for no consideration. Following such transaction, Sponsor holds no shares of Common Stock. As a result of Sponsor's pro rata distribution of shares to its members, (i) Fund III, a member of Sponsor, acquired 2,692,459 shares of Common Stock; (ii) Fund V, a member of Sponsor, acquired 1,704,862 shares of Common Stock; and (iii) Master Fund, a member of Sponsor, acquired 130,865 shares of Common Stock.Item 4 of the SCHEDULE 13D/A filed 2026-07-06

Timeline

Swipe the table sideways to see every column.

Questions about who owns BridgeBio Oncology Therapeutics, Inc.

Who owns BridgeBio Oncology Therapeutics, Inc.?

On this page, 6 holders' latest ownership filings report 5% or more of BridgeBio Oncology Therapeutics, Inc.: Helix Holdings II LLC (22.6%, Schedule 13D/A, filed 2025-08-13), Bihua Chen (22.32%, Schedule 13D/A, filed 2026-07-06), BridgeBio Pharma LLC (17.5%, Schedule 13D, filed 2025-08-18), Deerfield Management Company, L.P. (6.17%, Schedule 13G, filed 2025-08-18) and BC Global Opportunities IX LP (5.5%, Schedule 13G, filed 2025-09-03); 1 more is listed above.

Who are the largest shareholders of BridgeBio Oncology Therapeutics, Inc.?

By the share each holder's latest filing reports, the largest holders of BridgeBio Oncology Therapeutics, Inc. on this page are Helix Holdings II LLC (22.6%), Bihua Chen (22.32%) and BridgeBio Pharma LLC (17.5%).

When did Helix Holdings II LLC buy into BridgeBio Oncology Therapeutics, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Helix Holdings II LLC on this page is the Schedule 13D/A, filed 2025-08-13, reporting 22.6%. That earliest filing is itself an amendment, which updates an earlier report.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 9 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for BridgeBio Oncology Therapeutics, Inc.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for BridgeBio Oncology Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when BridgeBio Oncology Therapeutics, Inc. is mentioned again
• Find former BridgeBio Oncology Therapeutics, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes